孟鲁司特治疗轻中度慢性阻塞性肺疾病稳定期患者疗效观察

目的研究孟鲁司特对轻中度慢性阻塞性肺疾病稳定期患者肺功能和血清白介素8的影响。方法选择轻中度慢性阻塞性肺疾病稳定期患者共60例,随机分为两组,各30例。两组均予相同治疗,治疗组同时加用孟鲁司特片,每晚口服1次,每次10mg,疗程3个月。观察两组治疗前与治疗后1个月、3个月肺功能改变和血清白介素8水平。结果治疗组FEV1/FVC、FEV1占预计值百分比与治疗前比较均明显改善（P〈0.01）,而对照组患者治疗前后肺功能并无明显改善（P〉0.05）,与对照组治疗后比较,治疗组肺功能明显改善（P〈0.01）。治疗组治疗后血清IL-8水平明显降低（P〈0.01）;而对照组患者治疗前后血清IL-8水平并无明显降低（P〉0.05）,与对照组治疗后比较,治疗组血清IL-8均明显下降（P〈0.01）。结论轻中度慢性阻塞性肺疾病稳定期患者用孟鲁司特治疗肺功能改善明显,白介素8水平下降。

Therapeutic Effect of Montelukast on Mild and Moderate COPD in Stable Phase

Objective To study the effect of montelukast on pulmonary function and serum interleukin-8（IL-8） of patients with mild and moderate chronic obstructive pulmonary disease （COPD） in stable phase. Methods 60 patients with mild and moderate COPD were randomly divided into two groups：treatment group and control group,each having 30 cases. Both groups received the same therapy,but the patients in treatment group were additionally given 10mg montelukast qn for 3 months. The changes of pulmonary function and serum IL-8 in each group were observed before and 1,3 month after theray. Results FEV1/FVC、FEV1/prediction value of treatment group after therapy were significantly higher than those before therapy（P0.01）. No significant difference of pulmonary function indexes was found in control group after therapy（P0.05）. The plumonary function indexes of treatment group was significantly improved than that of control group after therapy（P0.01）. The level of serum IL-8 was significantly decreased in treatment group after therapy（P0.01）. No significant difference of serum IL-8 was found in control group after therapy（P0.05）. The serum IL-8 level of treatment group was significant lower than that of control group after therapy （P0.01）. Conclusion Montelukast can improve pulmonary function indexes and decrease serum IL-8 level in patients with mild and moderate COPD in stable phase.